Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 5/20 | 0.51 |
| ▸ | ITGAV | P06756 | 5/20 | 0.51 |
| ▸ | ITGB5 | P18084 | 5/20 | 0.51 |
| ▸ | ITGB1 | P05556 | 2/20 | 0.51 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.51 |
| ▸ | ITGB6 | P18564 | 1/20 | 0.51 |
| ▸ | ITGB8 | P26012 | 1/20 | 0.51 |
| ▸ | PDE10A | Q9Y233 | 4/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.36 |
| ▸ | PDE4A | P27815 | 2/20 | 0.36 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.36 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.36 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.36 |
| ▸ | HTR1A | P08908 | 1/20 | 0.32 |
| ▸ | DRD2 | P14416 | 1/20 | 0.32 |
| ▸ | DRD4 | P21917 | 1/20 | 0.32 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13264843 | 0.89 | ITGAV (0.52) | ITGB3ITGAVITGB5ITGB1ITGA5 | |
| SCHEMBL275472 | 0.89 | ITGB3 (0.41) | ITGB3ITGAVITGB5ITGB1ITGA5 | |
| SCHEMBL13823051 | 0.88 | ITGAV (0.52) | ITGB3ITGAVITGB5ITGB1ITGA5 | |
| SCHEMBL12348309 | 0.80 | ITGB3 (0.44) | ITGB3ITGAVITGB5ITGB1ITGA5 | |
| SCHEMBL2232307 | 0.79 | ITGB3 (0.44) | ITGB3ITGAVITGB5ITGB1ITGA5 | |
| SCHEMBL2232298 | 0.78 | ITGB3 (0.43) | ITGB3ITGAVITGB5ITGB1ITGA5 | |
| SCHEMBL2231372 | 0.78 | ITGB3 (0.40) | ITGB3ITGAVITGB5ITGB1ITGA5 | |
| SCHEMBL21776328 | 0.77 | ITGAV (0.69) | ITGB3ITGAVITGB5ITGB1ITGA5 | |
| SCHEMBL2233704 | 0.77 | ITGAV (0.39) | ITGB3ITGAVITGB5ITGB1ITGA5 | |
| SCHEMBL5584347 | 0.76 | ITGAV (0.69) | ITGB3ITGAVITGB5ITGB1ITGA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2070914-B1 | New antagonist derivatives of the vitronectin receptor, method for their preparation, their application as medicine and pharmaceutical compositions containing them | GALAPAGOS SAS (FR) | 2011-08-03 | — | — | EP | disclosed |
| US-7763621-B2 | Vitronectin receptor antagonist derivatives, method for preparing same, use thereof as medicines and pharmaceutical compositions containing same | GALAPAGOS SAS (FR) | 2010-07-27 | — | — | US | disclosed |
| US-7763621-B2 | Vitronectin receptor antagonist derivatives, method for preparing same, use thereof as medicines and pharmaceutical compositions containing same | GALAPAGOS SAS (FR) | 2010-07-27 | — | — | US | disclosed |
| US-7763621-B2 | Vitronectin receptor antagonist derivatives, method for preparing same, use thereof as medicines and pharmaceutical compositions containing same | GALAPAGOS SAS (FR) | 2010-07-27 | — | — | US | disclosed |
| US-7582640-B2 | Vitronectin receptor antagonist derivatives, method for preparing same, use thereof as medicines and pharmaceutical compositions containing same | GALAPAGOS SAS (FR) | 2009-09-01 | — | — | US | disclosed |
| US-7582640-B2 | Vitronectin receptor antagonist derivatives, method for preparing same, use thereof as medicines and pharmaceutical compositions containing same | GALAPAGOS SAS (FR) | 2009-09-01 | — | — | US | disclosed |
| US-7582640-B2 | Vitronectin receptor antagonist derivatives, method for preparing same, use thereof as medicines and pharmaceutical compositions containing same | GALAPAGOS SAS (FR) | 2009-09-01 | — | — | US | disclosed |
| EP-2070914-A1 | New antagonist derivatives of the vitronectin receiver, method for preparing same, application of same as medicine and pharmaceutical compositions containing them | Galapagos SAS (FR) | 2009-06-17 | — | — | EP | disclosed |
| US-20090149476-A1 | Novel vitronectin receptor antagonist derivatives, method for preparing same, use thereof as medicines and pharmaceutical compositions containing same | GALAPAGOS SAS | 2009-06-11 | — | — | US | disclosed |
| US-20090149476-A1 | Novel vitronectin receptor antagonist derivatives, method for preparing same, use thereof as medicines and pharmaceutical compositions containing same | GALAPAGOS SAS | 2009-06-11 | — | — | US | disclosed |
| US-20090149476-A1 | Novel vitronectin receptor antagonist derivatives, method for preparing same, use thereof as medicines and pharmaceutical compositions containing same | GALAPAGOS SAS | 2009-06-11 | — | — | US | disclosed |
| EP-1565467-B1 | NOVEL VITRONECTIN RECEPTOR ANTAGONIST DERIVATIVES, METHOD FOR PREPARING SAME, USE THEREOF AS MEDICINES AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | GALAPAGOS SAS (FR) | 2009-05-20 | — | — | EP | disclosed |
| US-20060052398-A1 | Novel vitronectin receptor antagonist derivatives, method for preparing same, use thereof as medicines and pharmaceutical compositions containing same | GALAPAGOS NV (BE) | 2006-03-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060052398-A1 | Novel vitronectin receptor antagonist derivatives, method for preparing same, use thereof as medicines and pharmaceutical compositions containing same | ADGRF1, C5AR2, ADGRE5 | ITGB3 244/4885ITGAV 206/4885ITGB5 111/4885 |
| US-20090149476-A1 | Novel vitronectin receptor antagonist derivatives, method for preparing same, use thereof as medicines and pharmaceutical compositions containing same | ADGRF1, C5AR2, ADGRE5 | ITGB3 244/4885ITGAV 206/4885ITGB5 111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.